Optimal timing of resumption of warfarin after intracranial hemorrhage.
Majeed
Ammar
A
Department of Hematology, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden.
Kim
Yang-Ki
YK
Roberts
Robin S
RS
Holmström
Margareta
M
Schulman
Sam
S
D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000453:epidemiology / Q000517:prevention & control; D002543:Cerebral Hemorrhage / Q000139:chemically induced*; D015331:Cohort Studies; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012008:Recurrence; D012189:Retrospective Studies; D018570:Risk Assessment; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control; D013997:Time Factors; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014859:Warfarin